Veligrotug for thyroid eye disease that returned after teprotumumab
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new medicine (veligrotug) for people with thyroid eye disease whose symptoms returned after completing teprotumumab. It aims to see if veligrotug can help again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with thyroid eye disease (TED).
- You must have completed a full 8-dose course of teprotumumab at least 9 months ago and it worked for you.
- Your thyroid eye disease symptoms must have come back after finishing that treatment.
- You need to have active signs of inflammation (score of 3 or higher on the eye activity scale).
- You must not have severe eye problems that put your vision at risk, and you must not be planning urgent eye surgery during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This trial tests a new version of an antibody treatment (teprotumumab) for people with active thyroid eye disease. It aims to reduce bulging and inflammation of the eyes, and you must have had symptoms for less than 9 months to join.
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
This trial compares two different lengths of treatment with Tepezza (teprotumumab) for thyroid eye disease. It aims to see if 4 treatments are as effective and safe as 8 treatments, which could mean fewer infusions for patients who respond early.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
This study tests a new medication (NTB003) for people with thyroid eye disease (TED), a condition that can cause bulging eyes, double vision, and discomfort. It aims to see if the treatment is safe and helps reduce symptoms.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.